Business
Taysha Gene Therapies to Host Manufacturing Day
Virtual event on Tuesday, July 27, 2021, at 10:00 a.m. ET will highlight the company’s unique three-pillar approach to manufacturing, its strategic
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nVirtual event on Tuesday, July 27, 2021, at 10:00 a.m. ET will highlight the company’s unique three-pillar approach to manufacturing, its strategic capabilities and other key considerations\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will host a virtual manufacturing day for analysts and investors. The event will be webcast live on Tuesday, July 27, 2021, from 10:00 a.m. to 1:00 p.m. ET.\n\nTopics of discussion will include the company’s unique three-pillar approach to the manufacturing process, its manufacturing capabilities, the regulatory environment for gene therapy manufacturing, and the immunology of gene therapy. A question and answer session will follow each formal presentation.\n\nThe event will feature presentations from Taysha senior leaders:\n\n\nFrederick Porter, Ph.D.\nChief Technical Officer, Taysha Gene Therapies\n\n\n\nGreg Gara\nSenior Vice President, Manufacturing, Taysha Gene Therapies\n\n\n\nSuyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM\nChief Medical Officer and Head of Research and Development, Taysha Gene Therapies\n\n\nRegistration for this event is available through LifeSci Events. A live video webcast will be available in the “Events & Media” section of the Taysha corporate website. An archived version of the event will be available on the website for 60 days.\n\nAbout Taysha Gene Therapies\n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.\n\nForward-Looking Statements\n\nThis press release contains forwa...